The Indian Council of Medical examination launched a clinical trial for a vaccine meant for preventing the TB occurrence among close contacts of a TB case patient. It is an important step in prevention and decreasing the burden of this disease.
Due to the highest number of TB cases in India, ICMR is undertaking this 1st TB vaccine clinical trial after decades of the famous BCG trial. Two potential vaccine candidates VPM 1002 and MIP (Mycrobacterium Indicus Pranii) were shortlisted after thorough analysis of all lead vaccine candidates, for phase Ⅲ vaccine trail in healthy household contacts of sputum smear-positive TB patient.
The safety and efficacy of these two vaccines will be evaluated in a single trial against the control group with no vaccine. The trial would enroll 12000 healthy Household contacts of sputum smear-positive TB cases that are at high risk of contracting the disease, from 7 sites of 6 states i.e. Delhi, Karnataka, Maharashtra, Orissa, Tamil Nadu and Telangana.
The approvals from all statutory regulatory bodies of India has been taken. The main aim of this clinical trial is to develop a vaccine that can completely eradicate TB.
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like